USCWA
ARMP icon

U.S. Capital Wealth Advisors’s Armata Pharmaceuticals ARMP Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio ARMP Stock Details ARMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,000
Closed -$4.96K – 691
2022
Q4 		$4.96K Buy
+4,000
New +$10.4K ﹤0.01% 1386

Other funds holding ARMP

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

U.S. Capital Wealth Advisors's ARMP Position: Q1 2023 in Review

U.S. Capital Wealth Advisors sold out of Armata Pharmaceuticals (ARMP) in Q1 2023, closing a stake of 4,000 shares — an estimated $4.96K sold.

U.S. Capital Wealth Advisors first reported a position in ARMP in Q4 2022 and held it in 1 quarter. The position peaked at $4.96K in Q4 2022. 23 funds tracked by Wall St. Rank hold ARMP as of Q1 2023.

  • U.S. Capital Wealth Advisors reported no remaining Armata Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • U.S. Capital Wealth Advisors sold 4,000 Armata Pharmaceuticals shares in Q1 2023, an estimated $4.96K.
  • U.S. Capital Wealth Advisors first reported a position in Armata Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • U.S. Capital Wealth Advisors's Armata Pharmaceuticals position peaked at $4.96K in Q4 2022.
  • 23 funds tracked by Wall St. Rank held Armata Pharmaceuticals as of Q1 2023.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2023, filed 11 May 2023.